Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence

<div>Comparison of polymyxin B combination treatments in different outcomes [<a href="/journals/ccrp/2017/3635609/#B45">45</a>]. PB: polymyxin B, CP: carbapenem, R: Rifampin, Ampi/Sul: Ampicillin/Sulbactam, and T: Tigecycline.</div>

Critical Care Research and Practice

fig3

Figure 3

Figure 3: Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence 